Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a treatment called high-flow nasal therapy (HFNT) can help people with interstitial lung disease (ILD) who have ongoing trouble breathing, even while using long-term oxygen therapy (LTOT). The goal is to see if HFNT can improve their breathing and overall quality of life. The trial is not yet recruiting participants, but it will include adults aged 65 to 74 who have had ILD and have experienced persistent difficulty breathing for at least three months while on LTOT.

To participate in this study, individuals must have been diagnosed with interstitial lung disease and have significant breathlessness. However, those with other chronic lung diseases like COPD or lung cancer, recent lung issues like a collapsed lung, or who are currently pregnant or breastfeeding will not be eligible. Participants can expect to receive either HFNT or continue their usual oxygen therapy, and their experiences will be monitored to assess any changes in their breathing and daily life. This study aims to find out which treatment is more effective for managing their symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Intertitial lung disease
• • Persistant dyspnea (mMRC≥3)
• • Long-term oxygen therapy at least for 3 months
• Exclusion Criteria:
• • Chronic respiratory disease (COPD, lung cancer)
• • Pneumothorax,
• • Pneumomediastinum,
• • Active smoker,
• • Patient on non-invasive ventilation or continuous positive airway pressure (CPAP),
• • Pregnancy or breastfeeding,
• • Unable to read or understand questionnaires,
• • No written consent,
• • Patients under guardianship,
• • No health assurance coverage